New study from deCODE genetics/Amgen highlights the importance of BMI in pathogenesis of disease, suggesting that reducing BMI alone could lower the risk of several diseases. Scientists at deCODE ...
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...
Infosys Knowledge Institute, a research arm of Infosys (NSE: INFY) (BSE: INFY) , a global leader in next-generation digital services and consulting, today unveiled a global research report titled ...
It also profiles the leading makers of antibody drugs, such as AbbVie and Amgen. The report focuses on how monoclonal ...
Fourth Frontier, a medical technology company based out of New York and Bangalore, announced the 510(k) clearance of the ...
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...
Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
